Title:Identification of 3-Bromo-1-Ethyl-1H-Indole as a Potent Anticancer Agent with Promising Inhibitory Effects on GST Isozymes
Volume: 21
Issue: 10
Author(s): Can Yılmaz, Sevki Arslan*, Dogukan Mutlu, Metin Konus, Abdussamet Kayhan, Aslıhan Kurt-Kızıldoğan, Çiğdem Otur, Omruye Ozok and Arif Kivrak*
Affiliation:
- Department of Biology, Faculty of Arts and Sciences, Pamukkale University, 20100, Denizli,Turkey
- Department of Chemistry, Van Yuzuncu Yil University, Van, 65080,Turkey
Keywords:
Indole, biological activities, cytotoxicity, antioxidant activity, antimicrobial activity, anti-cancer.
Abstract:
Background: Indole-based heterocyclic compounds play important roles in pharmaceutical chemistry
due to their unexpected biological and pharmacological properties.
Objective: Herein, we describe novel biological properties (antioxidant, antimicrobial and anti-cancer) of 3-
bromo-1-ethyl-1H-indole (BEI) structure.
Methods: BEI was synthesized from 1-Methyl-2-phenylindole and N-bromosuccinimide and was characterized
by using 1H and 13C NMR. Cytotoxicity was determined by MTT assay. Apoptosis analysis of BEI was determined
by Arthur™ image-based Cytometer. Different methods were applied to assess the antioxidant activity of
BEI. Molecular docking studies were conducted to determine the interactions of bonding between GST
isozymes and BEI.
Results: According to the antioxidant and antimicrobial activity assays, BEI compound showed reduced total
antioxidant activity compared to the Trolox standard, whereas it showed moderate antimicrobial activity against
Aspergillus niger and Phytophora eryhtrospora. Notably, the BEI compound demonstrated substantial selective
cytotoxicity for the first time towards cancer cell lines, and there existed a significant decrease in the percentage
of live cells treated with BEI, in comparison to the control ones. Interestingly, BEI exhibited a promising glutathione
S-transferase isozymes inhibition.
Conclusion: The results of this study suggest that BEI seems to be a promising molecule to be used in the design
of new anti-cancer agents that provide superiority to present commercial anti-cancer drugs.